Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2015

01.08.2015 | Epidemiology

Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing

verfasst von: Megan C. Roberts, Morris Weinberger, Stacie B. Dusetzina, Michaela A. Dinan, Katherine E. Reeder-Hayes, Melissa A. Troester, Lisa A. Carey, Stephanie B. Wheeler

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

It is unknown whether racial differences exist in adjuvant chemotherapy initiation among women with similar oncotype DX (ODX) risk scores. We examined whether adjuvant chemotherapy initiation varied by race. Data come from the Phase III, Carolina Breast Cancer Study, a longitudinal, population-based study of North Carolina women diagnosed with breast cancer between 2008 and 2014. We used modified Poisson regression and report adjusted relative risk (aRR) and 95 % confidence intervals (95 %CI) to estimate the association between race and adjuvant chemotherapy initiation across ODX risk groups among women who received the test (n = 541). Among women who underwent ODX testing, 54.2, 37.5, and 8.3 % of women had tumors classified as low-, intermediate-, and high-risk groups, respectively. We observed no racial variation in adjuvant chemotherapy initiation. Increasing ODX risk score (aRR = 1.39, 95 %CI = 1.22, 1.58) and being married (aRR = 2.92, 95 %CI = 1.12, 7.60) were independently associated with an increased likelihood of adjuvant chemotherapy in the low-risk group. Among women in the intermediate-risk group, ODX risk score (aRR = 1.15, 95 %CI = 1.11, 1.20), younger age (aRR = 1.95, 95 %CI = 1.35, 2.81), larger tumor size (aRR = 1.70, 95 %CI = 1.22, 2.35), and higher income were independently associated with increased likelihood of adjuvant chemotherapy initiation. No racial differences were found in adjuvant chemotherapy initiation among women receiving ODX testing. As treatment decision-making becomes increasingly targeted with the use of genetic technologies, these results provide evidence that test results may drive treatment in a similar way across racial subgroups.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Aizer AA, Chen MH, McCarthy EP et al (2014) Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 120(10):1532–1539CrossRefPubMed Aizer AA, Chen MH, McCarthy EP et al (2014) Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 120(10):1532–1539CrossRefPubMed
2.
Zurück zum Zitat Wheeler SB, Reeder-Hayes KE, Carey LA (2013) Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist 18(9):986–993PubMedCentralCrossRefPubMed Wheeler SB, Reeder-Hayes KE, Carey LA (2013) Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist 18(9):986–993PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Hershman D, McBride R, Jacobson JS et al (2005) Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23(27):6639–6646CrossRefPubMed Hershman D, McBride R, Jacobson JS et al (2005) Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23(27):6639–6646CrossRefPubMed
4.
Zurück zum Zitat Bickell NA, Wang JJ, Oluwole S et al (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24(9):1357–1362CrossRefPubMed Bickell NA, Wang JJ, Oluwole S et al (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24(9):1357–1362CrossRefPubMed
5.
Zurück zum Zitat Roberts MC, Wheeler SB, Reeder-Hayes K (2015) Racial/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J Public Health Apr 23:e1–e12 Roberts MC, Wheeler SB, Reeder-Hayes K (2015) Racial/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J Public Health Apr 23:e1–e12
6.
Zurück zum Zitat Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826CrossRefPubMed Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826CrossRefPubMed
7.
Zurück zum Zitat Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734CrossRefPubMed Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734CrossRefPubMed
8.
Zurück zum Zitat Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312CrossRefPubMed Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312CrossRefPubMed
9.
Zurück zum Zitat Lund MJ, Mosunjac M, Davis KM et al (2012) 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 118(3):788–796CrossRefPubMed Lund MJ, Mosunjac M, Davis KM et al (2012) 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 118(3):788–796CrossRefPubMed
10.
Zurück zum Zitat McGee SA, Durham DD, Tse CK, Millikan RC (2013) Determinants of breast cancer treatment delay differ for African American and White women. Cancer Epidemiol Biomark Prev 22(7):1227–1238CrossRef McGee SA, Durham DD, Tse CK, Millikan RC (2013) Determinants of breast cancer treatment delay differ for African American and White women. Cancer Epidemiol Biomark Prev 22(7):1227–1238CrossRef
11.
Zurück zum Zitat Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702–706CrossRefPubMed Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702–706CrossRefPubMed
12.
Zurück zum Zitat Zou GY, Donner A (2013) Extension of the modified Poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res 22(6):661–670CrossRefPubMed Zou GY, Donner A (2013) Extension of the modified Poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res 22(6):661–670CrossRefPubMed
13.
Zurück zum Zitat Hebert PL, Sisk JE, Howell EA (2008) When does a difference become a disparity? Conceptualizing racial and ethnic disparities in health. Health Aff (Millwood) 27(2):374–382CrossRef Hebert PL, Sisk JE, Howell EA (2008) When does a difference become a disparity? Conceptualizing racial and ethnic disparities in health. Health Aff (Millwood) 27(2):374–382CrossRef
14.
Zurück zum Zitat IOM (2014) Institute of Medicine (US) committee on understanding and eliminating racial and ethnic disparities in health care, Washington, DC IOM (2014) Institute of Medicine (US) committee on understanding and eliminating racial and ethnic disparities in health care, Washington, DC
15.
Zurück zum Zitat Roberts MC, Bryson A, Wheeler SB et al (2015) Barriers and facilitators for the use of oncotype DX use among oncologists: a qualitative study. In: Academy health annual research meeting, Minneapolis Roberts MC, Bryson A, Wheeler SB et al (2015) Barriers and facilitators for the use of oncotype DX use among oncologists: a qualitative study. In: Academy health annual research meeting, Minneapolis
16.
Zurück zum Zitat Lund MJ, Brawley OP, Ward KC et al (2008) Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat 109(3):545–557CrossRefPubMed Lund MJ, Brawley OP, Ward KC et al (2008) Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat 109(3):545–557CrossRefPubMed
17.
Zurück zum Zitat Wheeler SB, Carpenter WR, Peppercorn J et al (2012) Predictors of timing of adjuvant chemotherapy in older women with hormone receptor-negative, stages II-III breast cancer. Breast Cancer Res Treat 131(1):207–216CrossRefPubMed Wheeler SB, Carpenter WR, Peppercorn J et al (2012) Predictors of timing of adjuvant chemotherapy in older women with hormone receptor-negative, stages II-III breast cancer. Breast Cancer Res Treat 131(1):207–216CrossRefPubMed
18.
Zurück zum Zitat Enewold L, Zhou J, McGlynn KA et al (2012) Racial variation in breast cancer treatment among Department of Defense beneficiaries. Cancer 118(3):812–820PubMedCentralCrossRefPubMed Enewold L, Zhou J, McGlynn KA et al (2012) Racial variation in breast cancer treatment among Department of Defense beneficiaries. Cancer 118(3):812–820PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Du XL, Key CR, Osborne C (2004) Community-based assessment of adjuvant hormone therapy in women with breast cancer, 1991–1997. Breast J 10(5):433–439PubMedCentralCrossRefPubMed Du XL, Key CR, Osborne C (2004) Community-based assessment of adjuvant hormone therapy in women with breast cancer, 1991–1997. Breast J 10(5):433–439PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Hershman D, Weinberg M, Rosner Z et al (2003) Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 95(20):1545–1548CrossRefPubMed Hershman D, Weinberg M, Rosner Z et al (2003) Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 95(20):1545–1548CrossRefPubMed
21.
Zurück zum Zitat Hershman DL, Wang X, McBride R et al (2006) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99(3):313–321CrossRefPubMed Hershman DL, Wang X, McBride R et al (2006) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99(3):313–321CrossRefPubMed
22.
Zurück zum Zitat Fedewa SA, Ward EM, Steward AK, Edge SB (2010) Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004–2006. J Clin Oncol 28(27):4135–4141CrossRefPubMed Fedewa SA, Ward EM, Steward AK, Edge SB (2010) Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004–2006. J Clin Oncol 28(27):4135–4141CrossRefPubMed
23.
Zurück zum Zitat Aizer AA, Chen MH, McCarthy EP et al (2013) Marital status and survival in patients with cancer. J Clin Oncol 31(31):3869–3876CrossRefPubMed Aizer AA, Chen MH, McCarthy EP et al (2013) Marital status and survival in patients with cancer. J Clin Oncol 31(31):3869–3876CrossRefPubMed
24.
Zurück zum Zitat Bremnes RM, Andersen K, Wist EA (1995) Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 31A(12):1955–1959CrossRefPubMed Bremnes RM, Andersen K, Wist EA (1995) Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 31A(12):1955–1959CrossRefPubMed
25.
Zurück zum Zitat Hayman JA, Fairclough DL, Harris JR, Weeks JC (1997) Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol 15(3):1252–1260PubMed Hayman JA, Fairclough DL, Harris JR, Weeks JC (1997) Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer. J Clin Oncol 15(3):1252–1260PubMed
26.
Zurück zum Zitat Guth AA, Fineberg S, Fei K, Franco R, Bickell NA (2013) Utilization of oncotype DX in an inner city population: race or place? Int J Breast Cancer 2013:653805PubMedCentralCrossRefPubMed Guth AA, Fineberg S, Fei K, Franco R, Bickell NA (2013) Utilization of oncotype DX in an inner city population: race or place? Int J Breast Cancer 2013:653805PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Hassett MJ, Silver SM, Hughes ME et al (2012) Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 30(18):2218–2226PubMedCentralCrossRefPubMed Hassett MJ, Silver SM, Hughes ME et al (2012) Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 30(18):2218–2226PubMedCentralCrossRefPubMed
Metadaten
Titel
Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing
verfasst von
Megan C. Roberts
Morris Weinberger
Stacie B. Dusetzina
Michaela A. Dinan
Katherine E. Reeder-Hayes
Melissa A. Troester
Lisa A. Carey
Stephanie B. Wheeler
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2015
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3518-9

Weitere Artikel der Ausgabe 1/2015

Breast Cancer Research and Treatment 1/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.